Loading...
 
Mediterr J Rheumatol 2015; 26(2): 18-42
Evidence based treatment of systemic vasculitides
Authors Information

Clinical Immunology-Rheumatology Unit, 2nd Department of Internal Medicine and Laboratory, Athens Medical School, Hippocration General Hospital, Athens

Abstract
Systemic vasculitides comprise a wide spectrum of diseases with high mortality and morbidity when not treated appropriately. In this paper, a systematic review of the suggested treatment regimens was performed under the scope of recent data regarding the use of biologic agents for the treatment of systemic vasculitides. For Takayasu arteritis and giant-cell arteritis, classic corticosteroid therapy as well as the use of conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and the role of biologic therapies for resistant or relapsing cases is discussed. In antineutrophil cytoplasmic autoantibodies (ANCA) associated vasculitides, treatment depends on disease severity and here we discuss the indications of a recently approved biologic agent that depletes B lymphocytes (rituximab). Data on adult Immunoglobulin A (IgA) vasculitis are scarce and are mainly derived from studies in children. Regarding Behcet’s disease, treatment regimens are suggested based on organ involvement and new data are presented for newer treatment options in resistant or relapsing cases. A special mention is made for the need of collaboration between the rheumatologist and hepatologist in secondary virus-associated (HBV, HCV) forms of cryoglobulinemic vasculitis and polyarteritis nodosa. Finally, we discuss the indications of non drug treatments, such as plasma exchange, for life threatening cases of ANCA associated or cryoglobulinemic vasculitis.
Full Text
This paper is written in Greek only
References
  1. Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med. 1994;120:919-929.
  2. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68:318-323.
  3. Comarmond C, Plaisier E, Dahan K, et al. Anti TNF-α in refractory Takayasu’s arteritis: cases series and review of the literature. Autoimmun Rev. 2012;11:678-684.
  4. Pipitone N, Olivieri I, Salvarani C. Recommendations of the Italian Society of Rheumatology for the treatment of the primary large-vessel vasculitis with biological agents. Clin Exp Rheumatol. 30(1 Suppl 70):S139-S161.
  5. Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken). 2012;64:1720-1729.
  6. Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49:1594-1597.
  7. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68:310-317.
  8. Ntatsaki E, Carruthers D, Chakravarty K, et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford). 2014;53:2306-2309.
  9. De Groot K, Harper L, Jayne DRW, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150:670-680.
  10. Jones RB, Tervaert JWC, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211-220.
  11. Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369:417-427.
  12. Stassen PM, Tervaert JWC, Stegeman CA. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis. 2007;66:798-802.
  13. Hu W, Liu C, Xie H, Chen H, Liu Z, Li L. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant. 2008;23:1307-1312.
  14. Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient. Kidney Int. 2012;82:840-856.
  15. Silva F, Specks U, Kalra S, et al. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement--a prospective, open-label pilot trial. Clin J Am Soc Nephrol. 2010;5:445-453.
  16. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771-1780.
  17. Smith RM, Jones RB, Guerry M-J, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64:3760-3769.
  18. Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790-2803.
  19. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221-232.
  20. Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol. 2007;19:25-32.
  21. Cartin-Ceba R, Keogh KA, Specks U, Sethi S, Fervenza FC. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant. 2011;26:2865-2871.
  22. Pepper RJ, Fabre MA, Pavesio C, et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford). 2008;47:1104-1105.
  23. Floege J, Feehally J. Treatment of IgA nephropathy and Henoch-Schönlein nephritis. Nat Rev Nephrol. 2013;9:320-327.
  24. Pillebout E, Alberti C, Guillevin L, Ouslimani A, Thervet E. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura. Kidney Int. 2010;78:495-502.
  25. Kalliakmani P, Benou E, Goumenos DS. Cyclosporin A in adult patients with Henoch-Schönlein purpura nephritis and nephrotic syndrome; 5 case reports. Clin Nephrol. 2011;75:380-383.
  26. Nikibakhsh AA, Mahmoodzadeh H, Karamyyar M, et al. Treatment of complicated henoch-schönlein purpura with mycophenolate mofetil: a retrospective case series report. Int J Rheumatol. 2010;2010:254316.
  27. Ren P, Han F, Chen L, Xu Y, Wang Y, Chen J. The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schönlein purpura nephritis. Am J Nephrol. 2012;36:271-277.
  28. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. N Engl J Med. 1999;341:1284-1291.
  29. Davatchi F. Diagnosis/Classification Criteria for Behcet’s Disease. Patholog Res Int. 2012;2012:607921.
  30. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med. 1990;322:281-285.
  31. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet’s syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40:769-774.
  32. Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br J Ophthalmol. 2010;94:284-288.
  33. Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121:785-796.
  34. Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behcet’s disease: experience in 19 patients. Rheumatology. 2012;51:1825-1831.
  35. Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656-1662.
  36. Baki K, Villiger PM, Jenni D, Meyer T, Beer JH. Behcet’s disease with life-threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab treatment. Ann Rheum Dis. 2006;65:1531-1532.
  37. Iwata S, Saito K, Yamaoka K, et al. Effects of anti-TNF-  antibody infliximab in refractory entero-Behcet’s disease. Rheumatology. 2009;48:1012-1013.
  38. Yurdakul S, Mat C, Tüzün Y, et al. A double-blind trial of colchicine in Behçet’s syndrome. Arthritis Rheum. 2001;44:2686-2692.
  39. Hatemi G, Silman A, Bang D, et al. Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis. 2009;68:1528-1534.
  40. Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet’s disease--review and basis for recommendations. Rheumatology (Oxford). 2007;46:736-741.
  41. Akman-Demir G. Clinical patterns of neurological involvement in Behcet’s disease: evaluation of 200 patients. Brain. 1999;122:2171-2182.
  42. Giardina A, Ferrante A, Ciccia F, Vadalà M, Giardina E, Triolo G. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet’s disease refractory to standard immunosuppressive drugs. Rheumatol Int. 2011;31:33-37.
  43. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behçet’s disease: a double blind, placebo controlled study. J Rheumatol. 2005;32:98-105.
  44. Terrier B, Cacoub P. Cryoglobulinemia vasculitis: an update. Curr Opin Rheumatol. 2013;25:10-18.
  45. Terrier B, Krastinova E, Marie I, et al. Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood. 2012;119:5996-6004.
  46. Terrier B, Launay D, Kaplanski G, et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care Res (Hoboken). 2010;62:1787-1795.
  47. Mahr A, Chaigne-Delalande S, De Menthon M. Therapeutic plasma exchange in systemic vasculitis: an update on indications and results. Curr Opin Rheumatol. 2012;24:261-266.
  48. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63:199-236.
  49. Vassilopoulos D, Calabrese LH. Hepatitis C virus infection and vasculitis: implications of antiviral and immunosuppressive therapies. Arthritis Rheum. 2002;46:585-597.
  50. Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med. 2013;369:1035-1045.
  51. Vassilopoulos D, Calabrese LH. HCV Treatments and Their Integration Into Rheumatology. Curr Rheumatol Rep. 2015;17:526.
  52. Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:835-842.
  53. De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:843-853.
  54. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1-11.
  55. Pagnoux C, Seror R, Henegar C, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum. 2010;62:616-626.
  56. Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011;90:19-27.
  57. Ribi C, Cohen P, Pagnoux C, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: A prospective randomized study of one hundred twenty-four patients. Arthritis Rheum. 2010;62:1186-1197.
  58. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996;75:17-28.
  59. Guillevin L, Cohen P, Mahr A, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum. 2003;49:93-100.
  60. Gayraud M, Guillevin L, le Toumelin P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum. 2001;44:666-675.
  61. Lampertico P, Maini M, Papatheodoridis G. Optimal Management of Hepatitis B Virus Infection - EASL Special Conference. J Hepatol. 2015.
  62. Hernández-Rodríguez J, Hoffman GS. Updating single-organ vasculitis. Curr Opin Rheumatol. 2012;24:38-45.